Is 'Sticky Gunk' In Your Brain The Reason Behind Alzheimer's Disease?

Updated Mar 20, 2025 | 08:53 AM IST

SummaryThe new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years.
Alzheimer's Disease

Credits: Canva

An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

End of Article

Ivonescimab: Why Did US FDA Reject China's Promising Lung Cancer Drug?

Updated Nov 16, 2026 | 10:53 AM IST

SummaryThe FDA's decision came after a late-stage clinical trial showed that ivonescimab significantly delayed disease progression but failed to demonstrate a statistically significant improvement in overall survival (OS), a key measure of how long patients live after starting treatment.
Ivonescimab: Why Did The US FDA Reject China's Promising Lung Cancer Drug?

Credit: iStock

Ivonescimab, a much-anticipated lung cancer drug developed by China's Akeso in partnership with US-based Summit Therapeutics, has been rejected by the US Food and Drug Administration (FDA).

The drug, a PD-1 x VEGF bispecific antibody, was being evaluated in combination with chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer had progressed after treatment with EGFR-targeted drugs.

The FDA's decision came after a late-stage clinical trial showed that ivonescimab significantly delayed disease progression but failed to demonstrate a statistically significant improvement in overall survival (OS), a key measure of how long patients live after starting treatment.

In its Complete Response Letter (CRL), the regulator said the improvement in progression-free survival (PFS), without a statistically significant OS benefit, "did not establish a favorable benefit-risk profile to support approval".

Why Did The FDA Reject Ivonescimab?

Also read: 1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk Factors

The FDA's decision was based on findings from the Phase III HARMONi trial, which compared ivonescimab plus platinum-based chemotherapy with chemotherapy alone.

The combination reduced the risk of disease progression or death by 48% compared with chemotherapy alone, meeting the trial's primary PFS endpoint.

However, the primary overall survival analysis did not demonstrate a statistically significant benefit. This meant that although patients receiving ivonescimab experienced a delay in their cancer worsening, the trial did not establish that the treatment helped them live significantly longer.

Summit subsequently submitted updated analyses based on longer follow-up. The company said these showed a consistent survival benefit across Asian and Western patient groups.

However, the FDA maintained that the available evidence did not establish the survival benefit needed to support approval.

What Is Ivonescimab And How Does It Work?

Ivonescimab is an investigational PD-1 x VEGF bispecific antibody designed to target two proteins involved in cancer growth and immune evasion.

PD-1 is an immune checkpoint protein that cancer cells can exploit to evade immune attacks. Blocking this pathway can help the immune system recognize and attack cancer cells.

VEGF, meanwhile, helps tumors develop new blood vessels that supply oxygen and nutrients, supporting their growth. Blocking VEGF can interfere with this process.

By targeting both pathways, ivonescimab combines two approaches to fighting cancer: helping the immune system attack tumors and disrupting the blood supply that supports their growth.

The drug is administered through an intravenous infusion.

Could Ivonescimab Still Become A Rival To Keytruda?

Read More: IARC Says Low-Dose CT Can Cut Lung Cancer Deaths: AIIMS Expert Explains Why India Needs Its Own Screening Evidence

Ivonescimab had attracted considerable attention because of its dual-targeting approach and potential applications beyond lung cancer.

Its developers had hoped that the drug could eventually challenge Merck's Keytruda, one of the world's best-selling cancer medicines.

Several major pharmaceutical companies, including Merck and Pfizer, are also exploring therapies that combine immune checkpoint inhibition with VEGF targeting.

However, cancer researchers have cautioned against assuming that promising early results will translate into broad clinical benefits across different cancer types.

The FDA's rejection concerns a specific lung cancer indication and does not automatically determine the outcome of ivonescimab trials in other cancers.

What Happens Next?

Despite the regulatory setback, ivonescimab's development programme continues.

Summit is evaluating the drug in several other cancers, including non-small cell lung cancer, colorectal cancer, urothelial cancer and renal cell carcinoma.

The company and Akeso have reported five positive Phase III studies across their development programmes and have said they remain committed to advancing the drug.

End of Article

New Chinese Weight-Loss Injection Ribupatide Shows Over 17% Weight Loss In 48 Weeks: Could It Rival Mounjaro?

Updated Nov 16, 2026 | 07:43 AM IST

SummaryRibupatide, an experimental weight loss injection being developed in China, showed promise in recent clinical trial by delivering at least 17.7% weight loss in 48 weeks.
New Chinese Weight-Loss Injection Ribupatide Shows Over 17% Weight Loss In 48 Weeks: Could It Rival Mounjaro?

Credit: AI-generated image

An experimental weight loss injection developed in China has produced an average weight reduction of 17.7% over 48 weeks in adults who are overweight or obese, raising the possibility of another contender entering in the rapidly expanding obesity drug market.

The drug, called ribupatide, was evaluated in a Phase 3 clinical trial published in JAMA recently. Researchers found that participants receiving the highest dose lost nearly one-fifth of their starting body weight in 11 months.

How Much Weight Did Participants Lose?

The randomised trial involved 567 adults with overweight or obesity across 55 medical centres in China. Participants did not have diabetes and their average age was 34 years.

Researchers randomly assigned them to receive once-weekly injections of ribupatide at doses of 2 mg, 4 mg or 6 mg, or a placebo. All participants also received lifestyle counselling. After 48 weeks, the average weight reduction was:

  • 2 mg dose: 10.7%
  • 4 mg dose: 16.4%
  • 6 mg dose: 17.7%
  • Placebo: 1.4%

The researchers also examined how many participants lost at least 5% of their starting weight. This threshold was achieved by 68.1% of those receiving 2 mg, 88% in the 4 mg group and 85.7% in the 6 mg group, compared with 16% of participants receiving placebo.

Notably, weight loss had not clearly plateaued in the two higher-dose groups by the end of the study. This suggests that a longer treatment period may reveal further reductions.

Also read: Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

More About Ribupatide

Ribupatide, also known as HRS9531, is a dual-acting injectable medication that targets the GLP-1 and GIP hormones. These gut hormones help regulate appetite, digestion and blood glucose levels. By activating their receptors, the drug helps reduce hunger and increase feelings of fullness, helping people consume fewer calories.

This is similar to that of tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound. Both medicines target GLP-1 and GIP receptors.

Could Ribupatide Rival Mounjaro?

The trial results have drawn comparisons with existing weight loss drugs like Mounjaro and Wegovy. However, the comparisons need to be interpreted carefully.

In the SURMOUNT-1 trial, tirzepatide produced average weight loss of up to 20.9% after 72 weeks in adults with obesity or overweight without diabetes. Semaglutide 2.4 mg, marketed as Wegovy, produced an average reduction of 14.9% after 68 weeks in the STEP 1 trial.

Ribupatide's highest-dose group recorded 17.7% weight loss after 48 weeks. But these results come from separate clinical trials. A direct comparison would be needed to determine how ribupatide performs against tirzepatide or semaglutide.

Also read: World Diabetes Day: Why Some Diabetes Patients May Not Be Suitable For GLP-1 Treatment, Experts Explain

Side Effects Of Ribupatide

Digestive problems were the most frequently reported side effectsin the ribupatide trial. Gastrointestinal side effects occurred in 47.9% of participants receiving the 2 mg dose, 58.2% in the 4 mg group and 63.1% in the 6 mg group. This compared to 23.1% of those receiving placebo.

Reported problems included nausea, vomiting and diarrhoea. Most were mild or moderate according to the findings.

The study had its limitations as the participants were relatively young, which means the findings may not apply equally to older adults. Additionally, the 48-week treatment period may not have captured the full effects of the higher doses. The study's smaller body-composition assessment also did not measure muscle strength.

Ribupatide is an investigational treatment and is not yet an approved weight-loss medication for routine use.

End of Article

US Loses Measles Elimination Status After 26 Years: What Does It Mean?

Updated Nov 16, 2026 | 12:18 PM IST

SummaryThe United States has lost its measles elimination status that it had obtained in 2000 after decades of public health efforts.
US Loses Measles Elimination Status After 26 Years: What Does It Mean?

Credit: AI-generated image

The United States has lost its measles elimination status after more than a year of sustained transmission, marking a major setback for a public health achievement the country obtained in 2000.

The decision by the Pan American Health Organization (PAHO) comes after a sharp rise in infections as the US reported more than 5,400 measles cases in 2026. PAHO is expected to formally announce the decision on November 17.

According to the US Centers for Disease Control and Prevention (CDC), the country had recorded 5,412 cases as of November 15, resulting in more than 590 hospitalisations and at least six deaths. Some states have reported additional fatalities. Cases have been confirmed in 45 states and Washington, DC.

The United States had maintained its measles elimination status for more than 25 years. However, outbreaks that began in 2025 continued spreading into 2026. Approximately one-third of this year's cases were linked to those ongoing outbreaks.

What Does Losing Measles Elimination Status Mean?

Also read: US Set To Lose Measles-Elimination Status After 26 Years: Prof Devi Sridhar Explains Reasons Behind Resurgence

Measles elimination does not mean a country has no cases of the disease. It means that local transmission has been interrupted and that occasional outbreaks do not lead to sustained community spread.

Under the World Health Organization's definition, a country loses elimination status when it cannot stop continuous local transmission for at least 12 months.

The United States first achieved measles elimination status in 2000, after decades of vaccination efforts dramatically reduced infections. Imported cases and smaller outbreaks still occurred, but public-health measures and vaccination coverage helped contain them.

The current situation is different because the virus has continued circulating through communities for more than a year, creating ongoing chains of transmission.

CBS News medical correspondent Dr Céline Gounder explained the implications, "It means that we're at risk of being exposed to measles and getting measles if we're not vaccinated," Gounder said. "It means ERs and pediatricians need to consider measles in anyone with a fever and rash, whether they've traveled overseas or not. And we may now become an exporter of measles to other countries."

Measles Cases Are Rising In The US

Also read: US Measles Cases Cross 5,000 For First Time Since 1991; Country Risks Losing Elimination Status

Declining childhood vaccination coverage has left more communities vulnerable to outbreaks. Measles is among the most contagious infectious diseases, and the virus can spread rapidly when it enters populations with gaps in immunity.

According to CDC data, 96% of people infected in 2026 were either unvaccinated or had an unknown vaccination status. Only 2% of reported cases were among people who were fully vaccinated.

The country recorded 2,242 cases in 2025, its highest annual total in more than three decades at the time. The number has more than doubled in 2026.

The country has reported 10 measles-related deaths this year as of November 14. Pennsylvania has reported the largest outbreak, with more than 1,500 cases and seven deaths. Wisconsin has reported two child deaths, while New York recorded its first measles death in more than 30 years.

How Can US Regain Measles Elimination Status?

People who have not received the measles vaccine are at the greatest risk of infection. However, infants who are too young to be vaccinated, pregnant women and people with weakened immune systems are the most vulnerable.

Measles can cause complications like pneumonia and encephalitis or inflammation of the brain. In some cases, it can lead to permanent neurological complications, hearing loss and death.

Children who have not received the recommended doses of the measles, mumps and rubella (MMR) vaccine are especially vulnerable.

The CDC recommends two doses of the MMR vaccine. According to the public health experts, two doses are approximately 97% effective against measles.

Losing elimination status does not mean the country cannot regain it. However, sustained efforts to interrupt transmission will be necessary.

PAHO recommends maintaining measles vaccination coverage of at least 95%, alongside strong disease surveillance, laboratory testing and rapid outbreak response. Dr Omer Awan, an epidemiologist and public health contributor for Forbes, explained the importance of vaccination.

"It's frustrating and heartbreaking ... because we have the tools to fight this. The tool is the MMR vaccine, which we know is 97% effective at preventing the onset of measles," Awan said.

End of Article